36
Participants
Start Date
December 31, 2014
Primary Completion Date
March 31, 2020
Study Completion Date
August 31, 2020
Bevacizumab
"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
Institut Paoli-Calmettes, Marseille
Centre François Baclesse, Caen
CHU Besançon, Besançon
Institut Claudius Regaud, Toulouse
Hôpital Saint André, Bordeaux
ICM Val d'Aurelle, Montpellier
Centre Eugène Marquis, Rennes
Centre Eugene Marquis, Rennes
CHR Bretonneau, Tours
Institut de cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain
Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers
Centre Oscar Lambret, Lille
CHU Strasbourg - Hôpital Civil, Strasbourg
Centre Léon Bérard, Lyon
Hôpital Saint-Louis, Paris
Hôpital Européen Georges Pompidou, Paris
Hôpital Henri Mondor, Créteil
Gustave Roussy, Cancer Campus, Grand Paris, Villejuif
Centre Antoine Lacassagne, Nice
UNICANCER
OTHER